CYP3A5*6与*3功能缺失等位基因携带者肾移植受者他克莫司剂量标准化暴露更低:纵向回顾性真实世界研究
该回顾性纵向队列研究纳入67个国家1461例成人肾移植受者,分析4293次他克莫司剂量标准化AUC0-24,排除CYP3A5*1/*1者。线性混合效应模型显示CYP3A5*6携带者剂量标准化AUC0-24较CYP3A5*3携带者低17%(P=0.015),谷浓度敏感性分析低20%(P=0.011),移植后第一年持续偏低。
要点
- CYP3A5*6携带者他克莫司剂量标准化暴露较*3携带者低17%–20%。
- CYP3A5*1/*6基因型暴露降低最明显(-39%)。
- 非洲出生独立关联AUC0-24高23%。
核心结论
- CYP3A5*6与CYP3A5*3功能缺失等位基因对他克莫司暴露存在差异效应。
研究设计与样本
- 回顾性纵向队列研究,纳入67个国家1461例成人肾移植受者,分析4293次他克莫司剂量标准化AUC0-24,排除CYP3A5*1/*1者,采用线性混合效应模型调整临床因素和 ancestry。
主要发现
- CYP3A5*6携带者剂量标准化AUC0-24较CYP3A5*3携带者低17%(P=0.015)。
- 剂量标准化谷浓度C0敏感性分析显示CYP3A5*6携带者暴露低20%(P=0.011)。
- 间隔分析显示移植后第一年他克莫司暴露持续偏低。
- CYP3A5*1/*6基因型剂量标准化AUC0-24较CYP3A5*3/*3低39%(P<0.001),CYP3A5*3/*6低18%(P=0.006)。
- 以出生国定义的非洲来源独立关联AUC0-24高23%(P<0.001)。
临床怎么用
- 肾移植受者CYP3A5基因分型应涵盖CYP3A5*6,尤其非洲裔人群。
- CYP3A5*6携带者可能需要更高他克莫司剂量以达目标暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacogenomic research has historically focused on individuals of European ancestry, leading to the underrepresentation of genetic variants common in non-European populations. This bias is exemplified by CYP3A5*6, a functionally consequential variant common in individuals of African ancestry (MAF: 11-19%) but virtually absent in Europeans (MAF: 0.15%). We conducted a retrospective, longitudinal cohort study using real-world data from 1,461 adult kidney transplant recipients across 67 countries, analyzing 4,293 dose-normalized 24-hour area-under-the-curve (AUC0-24) measurements of tacrolimus. Patients with CYP3A5*1/*1 were excluded. Linear mixed-effects models (LME) were used to assess the association between CYP3A5*6 carriage and tacrolimus exposure, adjusting for clinical factors and ancestry using both HLA-based principal components and country of birth. CYP3A5*6 carriers had a 17% lower dose-normalized AUC0-24 than CYP3A5*3 carriers (P = 0.015). Sensitivity analyses using dose-normalized trough concentrations (C0) confirmed these findings, with a 20% lower exposure in CYP3A5*6 carriers (P = 0.011). An interval-based analysis demonstrated persistently lower tacrolimus exposure across the first post-transplant year. All CYP3A5*6-containing genotypes showed significantly lower dose-normalized AUC0-24 compared to CYP3A5*3/*3, the most common genotype in European populations, with the largest reductions observed in CYP3A5*1/*6 (-39%; P < 0.001) and CYP3A5*3/*6 (-18%; P = 0.006). African origin, defined by country of birth, was independently associated with a 23% higher AUC0-24 (P < 0.001). This is the first study to demonstrate a differential effect on tacrolimus exposure between the CYP3A5*6 and CYP3A5*3 loss-of-function alleles. Our results may help bridge the ethnicity gap, advance the applicability of pharmacogenomic findings, and promote health equity.
引用
- Levens AD, Moes DJAR, Boer Y, et al. Lower Dose-Normalized Tacrolimus Exposure in CYP3A5*6 vs. *3 Loss-of-Function Allele Carriers: A Longitudinal Retrospective Real-World Study in Kidney Transplant Recipients. Clin Pharmacol Ther. 2025. PMID: 41431155. doi:10.1002/cpt.70162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。